At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 274 enrolled
Drug / intervention
VX-548 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
In Brief
A Phase 2 clinical trial evaluating VX-548, HB/APAP, and 2 other interventions for Acute Pain. Completed, enrolled 274 participants across 12 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedJul 2021
Primary CompletionFeb 2022
Study CompletionMar 2022
TodayJul 2026
First PostedJul 26, 2021
Enrollment StartJul 19, 2021
Primary CompletionFeb 17, 2022
Study CompletionMar 4, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.9 years ago
Interventions
VX-548drug
Tablets for oral administration.
HB/APAPdrug
Capsules for oral administration.
Placebo (matched to VX-548)drug
Placebo matched to VX-548 for oral administration.
Placebo (matched to HB/APAP)drug
Placebo matched to HB/APAP for oral administration.